Core Viewpoint - The stock of Maiwei (Shanghai) Biotechnology Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 30% over three consecutive trading days [1][2]. Group 1: Stock Trading Abnormality - The company's stock price increased significantly on August 29, September 1, and September 2, 2025, leading to a cumulative price deviation of over 30%, which is classified as abnormal trading behavior according to the Shanghai Stock Exchange regulations [1]. - The company conducted a self-examination and confirmed that there are no undisclosed significant matters or important information that could affect the stock price [2]. Group 2: Operational Status - The company reported that its production and operational activities are normal, with no significant changes in market conditions or industry policies, and no substantial fluctuations in production costs or sales [2]. - There are no major undisclosed events or information that could impact the stock trading, including mergers, debt restructuring, or asset injections [2]. Group 3: Media and Market Rumors - The company found no media reports or market rumors that could significantly affect its stock price, emphasizing that all relevant information should be based on official announcements made on the Shanghai Stock Exchange website [2]. Group 4: Board of Directors' Statement - The board of directors confirmed that there are no undisclosed matters that should be reported according to the relevant regulations, and they have not been made aware of any information that could significantly impact the stock price [3].